CN102988501B - Preparation method and application of Libiling tablet - Google Patents
Preparation method and application of Libiling tablet Download PDFInfo
- Publication number
- CN102988501B CN102988501B CN201210377532.8A CN201210377532A CN102988501B CN 102988501 B CN102988501 B CN 102988501B CN 201210377532 A CN201210377532 A CN 201210377532A CN 102988501 B CN102988501 B CN 102988501B
- Authority
- CN
- China
- Prior art keywords
- libiling
- tablets
- preparation
- extraction
- ethanol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a preparation method of a libiling tablet which is prepared from crude drugs including 500g of radix sophorae flavescentis, 250g of radix paeoniae alba and 150g of radix aucklandiae through supercritical extraction and microwave extraction, so that the content of sophocarpidine is greatly improved. The invention also provides the application of the libiling tablet in preparing a medicine for restraining proliferation of human melanoma cell, MV3 cell.
Description
Technical field
The present invention relates to the Chinese medicine preparation technical field, be specifically related to a kind of preparation method and application of Libiling tablets.
Background technology
Libiling tablets is recorded in Ministry of Public Health standard WS3-B-0639-91, by Radix Sophorae Flavescentis 500g, Radix Paeoniae Alba 250g, Radix Aucklandiae 150g, as crude drug, is made, can clearing away heat-damp and promoting diuresis.For hygropyretic dysentery, purge heat, the diseases such as stomachache.
In prior art, not yet there is Libiling tablets to adopt the report of supercritical and microwave technology extracting aspect preparation, and adopt the method that powder and decocting boil of beating, technique is coarse, backward, and impurity is many, causes patient's consumption excessive, be inconvenient to take, had a strong impact on this product and applied clinically.
Summary of the invention
Goal of the invention: in order to address the above problem, the object of the present invention is to provide a kind of preparation method of Libiling tablets.
Another object of the present invention is to provide a kind of Libiling tablets to suppress the application in human melanoma cell MV3 cell proliferation medicine in preparation.
Technical scheme: the objective of the invention is to realize by following scheme:
A kind of preparation method of Libiling tablets, by Radix Sophorae Flavescentis 500g, Radix Paeoniae Alba 250g, Radix Aucklandiae 150g, as crude drug, made, described method is comprised of the following step: get the Radix Aucklandiae, join in CO2 supercritical extraction device, ethanol is as entrainer, the percent by volume that entrainer accounts for total extractant is 4-6%, extracting pressure 15-30MPa, temperature 30-50 ℃, CO2 flow 1-3m1/g crude drug min, extraction time 150-180min, obtain supercritical extract, standby; Get all the other Chinese medicines, pulverize, add 70% ethanol of 2L, drop in microwave extracting apparatus and carry out microwave extracting, extraction power 400600W, extract 2 times, each 4-8 minute, combining extraction liquid, concentrated, be added on the D101 macroporous adsorptive resins, 50% ethanol elution, collect 5 times of amount column volume eluents, decompression recycling ethanol, concentrated and dry, obtain the microwave extraction thing, standby; Above-mentioned supercritical extract and microwave extraction thing are mixed, add starch, 70% ethanol granule processed, drying, tabletting, make 1600, every heavy 0.5g.
The preparation method of above-mentioned a kind of Libiling tablets, described CO
2the percent by volume that the supercritical extraction entrainer accounts for total extractant is 5%.
The preparation method of above-mentioned a kind of Libiling tablets, described microwave extracting power 500W extracts 6 minutes at every turn.
The preparation method of above-mentioned a kind of Libiling tablets, described CO
2the extracting pressure 20MPa of supercritical extraction, 40 ℃ of temperature, CO
2flow 2ml/g crude drug min, extraction time 160min.
Above-mentioned Libiling tablets suppresses the application in human melanoma cell MV3 cell proliferation medicine in preparation.
In prior art, every 0.5g of Libiling tablets, each 8,3 times on the one, the every 0.5g of Libiling tablets that adopts the present invention to be prepared into only needs 4 at every turn, within 1st, takes 2 times, has greatly reduced dose having under the condition of more active component.This conclusion can be by following evidence.
The comparison of matrine content in Libiling tablets prepared by test one, distinct methods
1, instrument and reagent Libiling tablets of the present invention: press embodiment 3 method preparations, use the 800g crude drug, through extraction, make 1600, every heavy 0.5g.Former Libiling tablets, by the preparation of ministry standard method, used the 800g crude drug, through extraction, makes 1600, every heavy 0.5g.Agilent 1200 high performance liquid chromatographs; The METTLERAE240 electronic analytical balance; Matrine reference substance (Nat'l Pharmaceutical & Biological Products Control Institute).
2, method
Chromatographic condition and system suitability: with octadecylsilane chemically bonded silica, be filler; Methanol-water-phosphoric acid (40:60:0.2) is mobile phase; The detection wavelength is 280nm.Number of theoretical plate is pressed the matrine peak and is calculated, and should be not less than 3000.
The preparation of reference substance solution: precision takes at 60 ℃ of drying under reduced pressure matrine reference substance of 4 hours appropriate, adds methanol and makes the solution of every 1ml containing 18 μ g, obtains.
The preparation of need testing solution: get Libiling tablets of the present invention and former Libiling tablets, porphyrize, mix, and gets 1g, accurately weighed, and precision adds 70% ethanol 20ml, close plug, and supersound process 10 minutes, centrifugal, get supernatant, obtain.
Algoscopy is accurate reference substance solution and each 20 μ l of need testing solution of drawing respectively, and the injection liquid chromatography, measure, and obtains.
3, result
Result shows, in Libiling tablets of the present invention, the content of matrine is the 1.47mg/ sheet; And in former Libiling tablets, the content of matrine is the 0.35mg/ sheet, in the situation that dose reduces, matrine content improves a lot.
Above-mentioned research shows, the Libiling tablets that adopts the present invention to prepare, the Libiling tablets that active constituent content is standby higher than the ministry standard legal system.
The specific embodiment
Form by the following examples, foregoing of the present invention is described in further detail again, but this should be interpreted as to the scope of the above-mentioned theme of the present invention only limits to following example, all technology realized based on foregoing of the present invention all belong to scope of the present invention.
Embodiment 1
Get Radix Sophorae Flavescentis 500g, Radix Paeoniae Alba 250g, Radix Aucklandiae 150g, by the Radix Aucklandiae, join in CO2 supercritical extraction device, ethanol is as entrainer, and the percent by volume that entrainer accounts for total extractant is 4%, extracting pressure 15MPa, 30 ℃ of temperature, CO2 flow 1m1/g crude drug min, extraction time 150min, obtain supercritical extract, standby; Get all the other Chinese medicines, pulverize, add 70% ethanol of 2L, drop in microwave extracting apparatus and carry out microwave extracting, extraction power 400W, extract 2 times, each 4 minutes, combining extraction liquid, concentrated, be added on the D101 macroporous adsorptive resins, 50% ethanol elution, collect 5 times of amount column volume eluents, decompression recycling ethanol, concentrated and dry, obtain the microwave extraction thing, standby; Above-mentioned supercritical extract and microwave extraction thing are mixed, add starch, 70% ethanol granule processed, drying, tabletting, make 1600, every heavy 0.5g.
After testing, in finished product, the content of matrine is the 1.51mg/ sheet.
Embodiment 2
Get Radix Sophorae Flavescentis 500g, Radix Paeoniae Alba 250g, Radix Aucklandiae 150g, by the Radix Aucklandiae, join CO
2in the supercritical extraction device, ethanol is as entrainer, and the percent by volume that entrainer accounts for total extractant is 6%, extracting pressure 30MPa, temperature 50 C, CO
2flow 3m1/g crude drug min, extraction time 180min, obtain supercritical extract, standby; Get all the other Chinese medicines, pulverize, add 70% ethanol of 2L, drop in microwave extracting apparatus and carry out microwave extracting, extraction power 600W, extract 2 times, each 8 minutes, combining extraction liquid, concentrated, be added on the D101 macroporous adsorptive resins, 50% ethanol elution, collect 5 times of amount column volume eluents, decompression recycling ethanol, concentrated and dry, obtain the microwave extraction thing, standby; Above-mentioned supercritical extract and microwave extraction thing are mixed, add starch, 70% ethanol granule processed, drying, tabletting, make 1600, every heavy 0.5g.
After testing, in finished product, the content of matrine is the 1.54mg/ sheet.
Embodiment 3
Get Radix Sophorae Flavescentis 500g, Radix Paeoniae Alba 250g, Radix Aucklandiae 150g, by the Radix Aucklandiae, join CO
2in the supercritical extraction device, ethanol is as entrainer, and the percent by volume that entrainer accounts for total extractant is 5%, extracting pressure 20MPa, 40 ℃ of temperature, CO
2flow 2m1/g crude drug min, extraction time 160min, obtain supercritical extract, standby; Get all the other Chinese medicines, pulverize, add 70% ethanol of 2L, drop in microwave extracting apparatus and carry out microwave extracting, extraction power 500W, extract 2 times, each 6 minutes, combining extraction liquid, concentrated, be added on the D101 macroporous adsorptive resins, 50% ethanol elution, collect 5 times of amount column volume eluents, decompression recycling ethanol, concentrated and dry, obtain the microwave extraction thing, standby; Above-mentioned supercritical extract and microwave extraction thing are mixed, add starch, 70% ethanol granule processed, drying, tabletting, make 1600, every heavy 0.5g.
After testing, in finished product, the content of matrine is the 1.47mg/ sheet.
Embodiment 4: Libiling tablets suppresses the experimentation data of MV3 cell proliferation
1 experiment material
1.1 experiment cell strain
Human melanoma cell MV3 cell, Nanjing Zhengkuan Pharmaceutical Technology Co., Ltd.'s laboratory cell bank, DMEM+10%FBS cellar culture.
1.2 Experimental agents
Drugs: Libiling tablets of the present invention: press embodiment 3 method preparations.
The medicinal liquid liquid storage: take the 100mg Libiling tablets, be dissolved in the 5ml dehydrated alcohol, 0.2 μ m filter filters, 500 μ ldoff pipe packing, and-20 ℃ of storages, 0.2 μ m filter filters the use of dehydrated alcohol in order to matched group simultaneously.
1.3 experiment reagent
The Cat.No.12100-061Lot.No.758137 of DMEM(GIBCO company); Hyclone (Hangzhoupro, sky, Zhejiang bio tech ltd Lot.No.100419); NaHCO3(Shanghai hundred million chemical reagent company limited Cat.No.11810-033Lot.No.1088387 of a specified duration); Trypsin(AMRESCO company lot number: 2010/04); EDTA(AMRESCO company lot number: 2009/10); Penicillin G Sodium Salt(AMRESCO company lot number: 2010242); Streptomycin Sulfate(AMRESCO company lot number: 2010382); Dehydrated alcohol (Nanjing Chemistry Reagent Co., Ltd.'s lot number: 080310182); MTT (Biosharp lot number: 0793); The autogamy of PBS(laboratory);
1.4 experiment equipment
Lycra inverted microscope (German Leica model: DM1L); Visible-ultraviolet light microwell plate detector (U.S. MD company model: SPECTRAMAX 190); CO2 incubator (FORMA model: 3111); (safe and sound company of Su Jing group manufactures model to super-clean bench: SW-CJ-ZFD); Pure water instrument (U.S. Spring company model: S/N020579); Accurate pipettor (French Gilson Inc model: P2); Electronic balance (German Sai Duolisi company limited model: BT323S); Full-automatic high-pressure autoclave (Japanese SANYO company model: MLS-3020); Table electrothermal air dry oven (Shanghai accurate experimental facilities company model: DHG9123A); Refrigerator (Siemens Company's model: KG18V21TI); Liquid nitrogen container (CBS model: 2001); Low speed centrifuge (Anting Scientific Instrument Factory, Shanghai's model: KA-1000); 0.2 μ m filter (MILLIPORE model: SLGP033RB); 10cm culture dish (NEST company), 96 well culture plates (NEST company); Cell counting count board; Centrifuge tube, pipet, Tips are some.
2 experimental techniques
1) the MV3 cell carries out cellar culture (10cm culture dish) with DMEM+10%FBS in 37 ℃, 5%CO2, when Growth of Cells during to logarithmic (log) phase, collecting cell, discard culture fluid, PBS fine laundering 3 times, add 3ml 0.25% trypsin-0.04%EDTA, after 37 ℃ of digestion 2min, add wherein 5ml complete medium neutralization reaction, after the piping and druming cell, it is proceeded in centrifuge tube, the centrifugal 5min of 1000rpm, adjust 3 * 104/ml of concentration of cell suspension.
2) the cell kind is entered in 96 well culture plates, every hole adds cell suspension 180 μ l, culture plate put into cell culture incubator (37 ℃, 5%CO2) cellar culture.
3) according to the Growth of Cells situation, generally grow to 50%-70%, add Libiling tablets solution, continue to cultivate 24h.
4) add 20 μ l MTT solution (5mg/ml, i.e. 0.5%MTT) after 24h, continue to cultivate 4h.
5) after 4h, the buckle method is removed supernatant, with absorbent paper, pats dry gently, and every hole adds 200 μ l dimethyl sulfoxide, puts low-speed oscillation 10min on shaking table, and crystal is fully dissolved.Measure the light absorption value in each hole at enzyme-linked immunosorbent assay instrument 490nm place.
6) background (do not add cell, only add culture fluid) is set simultaneously, control wells (the medicine dissolution medium of cell, same concentrations, culture fluid, MTT, dimethyl sulfoxide), set 6 multiple holes for every group.
7) with medicine, the suppression ratio to cell means result:
Cell increment suppression ratio (%)=(control wells OD value-dosing holes OD value)/control wells OD value * 100%.Experiment repeats 3 times.
3 statistical dispositions
Adopt correlation analysis and Student t check in Microsoft Excel 2003 softwares, data mean with mean ± S.D..
4 experimental results
Statistical result showed after the mtt assay experiment, with matched group, compare, when dosage reaches 5mg/ml, to MV3 cell inhibitory effect variant (P<0.05), dosage this difference when 10mg/ml has significance (P<0.01), and utmost point significant difference (P<0.001) is arranged when dosage reaches 15-20mg/ml.
Table 1 Libiling tablets is on MV3 cell inhibitory effect impact research
Annotate: compare * P<0.01 with matched group; * P<0.001
5 experiment conclusion
Libiling tablets can suppress the MV3 cell proliferation, reduces the Growth of Cells number of MV3 cell, and this effect is dose dependent.
Claims (4)
1. a Libiling tablets suppresses the application in human melanoma cell MV3 cell proliferation medicine in preparation, it is characterized in that Libiling tablets made as crude drug by Radix Sophorae Flavescentis 500g, Radix Paeoniae Alba 250g, Radix Aucklandiae 150g, preparation method is comprised of the following step: get the Radix Aucklandiae, join CO
2in the supercritical extraction device, ethanol is as entrainer, and the percent by volume that entrainer accounts for total extractant is 4-6%, extracting pressure 15-30MPa, temperature 30-50 ℃, CO
2flow 1-3ml/g crude drug min, extraction time 150-180min, obtain supercritical extract, standby; Get all the other Chinese medicines, pulverize, add 70% ethanol of 2L, drop in microwave extracting apparatus and carry out microwave extracting, extraction power 400-600W, extract 2 times, each 4-8 minute, combining extraction liquid, concentrated, be added on the D101 macroporous adsorptive resins, 50% ethanol elution, collect 5 times of amount column volume eluents, decompression recycling ethanol, concentrated and dry, obtain the microwave extraction thing, standby; Above-mentioned supercritical extract and microwave extraction thing are mixed, add starch, 70% ethanol granule processed, drying, tabletting, make 1600, every heavy 0.5g.
2. Libiling tablets suppresses the application in human melanoma cell MV3 cell proliferation medicine in preparation according to claim 1, it is characterized in that CO described in the preparation method of Libiling tablets
2the percent by volume that the supercritical extraction entrainer accounts for total extractant is 5%.
3. Libiling tablets suppresses the application in human melanoma cell MV3 cell proliferation medicine in preparation according to claim 1, it is characterized in that microwave extracting power 500W described in the preparation method of Libiling tablets, extracts 6 minutes at every turn.
4. Libiling tablets suppresses the application in human melanoma cell MV3 cell proliferation medicine in preparation according to claim 1, it is characterized in that CO described in the preparation method of Libiling tablets
2the extracting pressure 20MPa of supercritical extraction, 40 ℃ of temperature, CO
2flow 2ml/g crude drug min, extraction time 160min.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210377532.8A CN102988501B (en) | 2012-10-08 | 2012-10-08 | Preparation method and application of Libiling tablet |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210377532.8A CN102988501B (en) | 2012-10-08 | 2012-10-08 | Preparation method and application of Libiling tablet |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102988501A CN102988501A (en) | 2013-03-27 |
| CN102988501B true CN102988501B (en) | 2014-01-01 |
Family
ID=47917927
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210377532.8A Expired - Fee Related CN102988501B (en) | 2012-10-08 | 2012-10-08 | Preparation method and application of Libiling tablet |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102988501B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105596456A (en) * | 2016-03-01 | 2016-05-25 | 南京正亮医药科技有限公司 | Preparation method and application of spur pills |
| CN107243025A (en) * | 2017-06-26 | 2017-10-13 | 吉林大学 | A kind of plant drug composition for treating canine parvovirus disease |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102397451A (en) * | 2011-11-26 | 2012-04-04 | 苏州派腾生物医药科技有限公司 | Preparation method of cholagogic tablet |
-
2012
- 2012-10-08 CN CN201210377532.8A patent/CN102988501B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102397451A (en) * | 2011-11-26 | 2012-04-04 | 苏州派腾生物医药科技有限公司 | Preparation method of cholagogic tablet |
Non-Patent Citations (1)
| Title |
|---|
| 中华人民共和国***药典委员会.痢必灵片.《***药品标准 中药成方制剂分册（第三册）》.1991,第176页. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102988501A (en) | 2013-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102973667B (en) | Preparation method and application of cold-fever tablet | |
| CN102988526B (en) | Method for preparing Bailing tablets and application | |
| CN102988577B (en) | Preparation method and application of brain-soothing hypertension pill | |
| CN102988612B (en) | Preparation method and application of tablet for clearing away heat | |
| CN102988665B (en) | Method for preparing gynecological menstruation regulating tablets and application | |
| CN102988480B (en) | Method for preparing bile and patchouli rhinitis tablets and application | |
| CN102988545B (en) | Preparation method and application of Yulian tablet | |
| CN102988502B (en) | Preparation method and application of Desheng tablet | |
| CN102988489B (en) | Preparation method and application of nose comforting tablet | |
| CN103028005B (en) | Preparation method of anti-lumbago tablet and application thereof | |
| CN102988479B (en) | Preparation method and application of anti-dazzling tablet | |
| CN102988501B (en) | Preparation method and application of Libiling tablet | |
| CN102988614B (en) | Preparation method and application of antiphlogosis tablet | |
| CN102988550B (en) | Preparation method and application of qinlian tablet | |
| CN102836381B (en) | A kind of preparation method of regulating the spleen and stomach sheet and application | |
| CN102973749B (en) | Preparation method and applications of divaricate saposhnikovia-angelica archang lica rhinitis tablets | |
| CN102988500B (en) | Method for preparing compound Dantong tablets and application | |
| CN102988509B (en) | Preparation method and application of bone-knitting tablet | |
| CN102988611B (en) | Preparation method and application of antihypertension tablet | |
| CN102988881B (en) | Preparation method and application of pulse unblocking tablet | |
| CN102988522B (en) | Preparation method and application of naodesheng tablets | |
| CN102988691B (en) | Preparation method and application of liver-strengthening tablet | |
| CN102988576B (en) | Preparation method and application of nine-ingredient notopterygium root tablets | |
| CN102988836B (en) | Preparation method and application of Fuganning tablets | |
| CN102988749A (en) | Preparation method and application of body-building tablet |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: THE FIRST AFFILIATED HOSPITAL OF XINXIANG MEDICAL Free format text: FORMER OWNER: BIAN YUPING Effective date: 20131202 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| C53 | Correction of patent for invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Zhao Dean Inventor after: Li Hehua Inventor after: Li Yuanyuan Inventor after: Xu Huiqin Inventor before: The inventor has waived the right to be mentioned |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 211224 NANJING, JIANGSU PROVINCE TO: 453199 XINXIANG, HENAN PROVINCE Free format text: CORRECT: INVENTOR; FROM: REQUEST NOT TO RELEASE THE NAME TO: ZHAO DEAN LI HEHUA LI YUANYUAN XU HUIQIN |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20131202 Address after: 453199 No. 88 health Road, Weihui, Henan, Xinxiang Applicant after: The First Affiliated Hospital of Xinxiang Medical University Address before: Lishui County of Nanjing City, Jiangsu province 211224 Jing Qiao Zhen Chen Biancun Applicant before: Bian Yuping |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140101 Termination date: 20151008 |
|
| EXPY | Termination of patent right or utility model |